Answers are grounded in this paper and cite their sources.
Introduction Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is a leading cause of chronic liver disease globally. Its multifaceted pathogenesis is driven by insulin resistance, lipid toxicity, oxidative stress, and gut microbiota dysbiosis. Emerging evidence highlights that the depletion of beneficial gut commensals, particularly the Faecalibacterium genus, is a hallmark of MAFLD and correlates with disease severity. This review aims to systematically comprehensively evaluate the mechanistic interplay between Faecalibacteriu m and MAFLD progression, elucidating its metabolic, inflammatory, and barrier-protective roles, while exploring its translational potential as a next-generation probiotic (NGP). Methods A comprehensive literature search was conducted using PubMed and Web of Science for articles published up to early 2026. The search strategy utilized combinations of keywords including (“ Faecalibacterium ”) AND (“MAFLD” OR “NAFLD” OR “MASH” OR “steatohepatitis” OR “gut-liver axis”). Included studies encompassed in vitro mechanistic assays, animal models of fatty liver, and human clinical trials. To ensure the robustness of the synthesized evidence, the methodological quality and risk of bias of the included literature were strictly evaluated. Animal studies were assessed using the SYRCLE (Systematic Review Centre for Laboratory animal Experimentation) risk of bias tool, while observational clinical studies were evaluated utilizing the Newcastle-Ottawa Scale (NOS). Results Current evidence indicates that Faecalibacterium mitigates MAFLD through multi-targeted mechanisms mediated by its effectors, including short-chain fatty acids (SCFAs), microbial anti-inflammatory molecules (MAM), and extracellular vesicles (FEVs). These effectors ameliorate hepatocyte lipotoxicity, alleviate endoplasmic reticulum stress, and potently suppress the NF-κB inflammatory cascade, driving M2b macrophage polarization and restoring Th17/Treg balance. Furthermore, Faecalibacterium fortifies the intestinal dual-layer defense by upregulating tight junction proteins and mucin secretion, profoundly restricting portal lipopolysaccharide (LPS) translocation. Although translational challenges persist due to its strict anaerobic nature, interventions such as precision prebiotics and postbiotics show substantial promise. Conclusion Faecalibacterium represents a pivotal keystone taxon and a promising therapeutic target for MAFLD. Future research should prioritize elucidating strain-level functional heterogeneity and optimizing strictly anaerobic cultivation and delivery technologies to facilitate its clinical translation as a precision microbiome-based therapy.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: